20 results about "Diosmin" patented technology

The present invention relates to a method for producing diosmin in plants by reconstructing the diosmin biosynthetic pathway. Reconstructing the diosmin biosynthetic pathway by selecting optimal genes according to the present invention has the effect of enabling mass production of diosmin or a precursor thereof in plants, and therefore can be advantageously used for large-scale production of diosmin or a precursor thereof in the form of a gene expression cassette, a recombinant vector, a transformant, a transgenic plant, a method for producing a transgenic plant, or a method for producing diosmin or a precursor thereof.

The invention discloses a determination method for a dissolution curve of a citrus flavone tablet, and belongs to the technical field of pharmaceutical analysis. The method comprises the following steps: setting dissolution conditions, and preparing a dissolution medium which is a strong alkali solution with the mass volume ratio of 0.1-0.6% or a strong alkali and weak acid salt solution with the mass volume ratio of 1-2% and a Tween 80 solution with the mass volume ratio of 1-2%; the method comprises the following steps: setting liquid chromatography detection conditions, and adopting a Phenomenex Gemini chromatographic column; preparing a test solution and a reference solution; and finally, detecting the contents of diosmin and hesperidin in each solution according to a liquid chromatography to obtain dissolution rates at different time, and establishing a dissolution curve according to the dissolution rates and the dissolution time. The method has the advantages of scientificity, durability and reproducibility, the measured dissolution curve has distinguishing power, the in-vitro release behavior of the dissolution curve can be evaluated, guarantee is provided for quality consistency between batches of drugs, the method can also be used for quality consistency evaluation work of imitated drugs and originally developed preparations, and the medication curative effect is guaranteed.

The subject of the invention is a new medicinal combination. More specifically, the subject matter of the invention is a therapeutic combination for the treatment of venous insufficiency. More specifically, the subject of the invention is a combination of diosmin, folic acid and vitamin B6. It is also a subject matter of the invention to use the combination to prepare a pharmaceutical composition for the treatment of venous insufficiency and to use the combination or pharmaceutical composition according to the invention for the treatment of venous insufficiency. The results obtained with the compositions have shown that their use has contributed to a favourable therapeutic effect in all cases and that the reduction of homocysteine levels has been shown to have a positive effect on the cure of the disease even in the presence of normal or low homocysteine levels.

This invention discloses a method for preparing diosmin impurity compounds and their application, relating to the field of pharmaceutical impurity preparation technology. The preparation method includes the following steps: S1, preparation of compound IM-1: compound SM-1 and a methylating agent are heated under alkaline conditions to obtain compound IM-1; S2, preparation of compound formula 1: compound IM-1 is added to an alcohol solution, and an inorganic base is added under stirring. After the addition is complete, the mixture is kept warm and stirred, then cooled to 15-20°C, and dilute hydrochloric acid is added dropwise until the pH reaches 6.5-7. The mixture is concentrated to obtain the crude product of formula 1, and finally purified by thin-layer chromatography to obtain the pure product of formula I. This product can be used as a reference standard for the quality control of diosmin raw material, which helps to obtain a higher quality product.

The present invention relates to new solid forms (NSF) of a flavonoid and a coformer. The NSF are co-amorphous solids of flavonoids and amino acids, as well as the solvates of said co-amorphous solids. The flavonoid is selected from quercetin, genistein, fisetin, apigenin, naringenin, rutin, diosmin, among others. The coformer is selected from lysine and arginine. The NSF have enhanced stability, solubility and pharmacological properties over parent polyphenols. The new solid forms are suitable to be used in pharmaceutical compositions, food products, nutritional supplements and the like.

The application discloses a method for detecting iodine content in diltiaxin bulk drug and a quality control method of the iodine content, and belongs to the technical field of drug detection and quality control, and comprises the following steps: preparing a control solution of potassium iodide; dissolving the to-be-detected substance in a hydrazine solution after combustion to prepare a test solution; performing liquid chromatography detection on the control solution and the test solution to obtain corresponding chromatograms; and calculating the iodine content in the to-be-detected substance according to the concentration and peak area of the control solution and the concentration and peak area of the test solution in the chromatograms. The application can quantitatively detect the residual iodine content based on the liquid chromatography detection method, the analysis result is reliable, and the application has the advantages of high detection precision, simple operation steps, high detection efficiency and the like.

The present invention discloses an active component with antioxidant, anti-glycation and anti-inflammatory effects, as well as its preparation method and application. This component includes oleuropein, diosmin, neodiosmin, rosmarinic acid, oleuropein, salvianolic acid B, luteolin-7-O-glucoside, pectolinarigenin, ligustroside G13, 6'-O-trans-cinnamoyl-8-epigingkolic acid. Its preparation method uses Zhenzhu Tiaozhi Formula, Tongmai Formula, Baoshen Formula, etc. as raw materials, ultrasonic extraction with methanol, and the extract is separated and purified by preparative liquid chromatography or dynamic axial compression column chromatography, combined with real-time on-line ultraviolet spectrophotometric detection to obtain. Research shows that the active component of the present invention has good in vitro antioxidant, anti-glycation and anti-inflammatory activities, can significantly reduce the levels of inflammatory factors TNF-α and IL-1β in LPS-induced Raw 264.7 cells, and has a protective effect on LPS-induced liver and kidney damage in C57 / BL6J mice, and is suitable for application in the preparation of drugs for preventing or treating metabolic inflammatory diseases.

The invention discloses large-particle diosmin prepared based on a crystallization regulating agent and a method and application thereof, and relates to the technical field of diosmin synthesis, the method comprises the following steps: S1, dissolving diosmin in a sodium hydroxide aqueous solution, and adding hydrochloric acid to adjust the pH value of the solution to 10-11; s2, adding a crystallization regulator, namely polyvinylpyrrolidone, with the use amount of the crystallization regulator being 0.01%-0.1% of the weight of diosmin, stirring, and uniformly mixing; s3, hydrochloric acid is added, the pH value of a solution system is adjusted to be 6-7, stirring is conducted, diosmin is separated out, centrifugation and washing crystallization are conducted, crystals separated out after washing are dried, a large-particle diosmin finished product is obtained, the particle size of the obtained large-particle diosmin is increased by 2-4 times, the repose angle is optimized to be 30-35 degrees, and the large-particle diosmin is obviously superior to 40-45 degrees of a traditional technology, and the large-particle diosmin is obtained. The technical bottlenecks of small diosmin particle size and poor powder fluidity in the traditional process are effectively broken through.

The present invention belongs to the technical field of pharmaceuticals. Disclosed are a pharmaceutical composition for treating a TDP-43 proteinopathy, and a preparation method therefor and the use thereof. The pharmaceutical composition comprises at least one of each of compounds of class A and compounds of class B. The compounds of class A comprise at least one of sodium aescinate, a sodium aescinate derivative, hederagenin or a hederagenin derivative; and the compounds of class B comprise at least one of dehydrated icaritin, a dehydrated icaritin derivative, diosmin or a diosmin derivative. The pharmaceutical composition has a good therapeutic effect on the TDP-43 proteinopathy.

The invention belongs to the field of chemical synthesis, and particularly relates to a preparation method of diosmin. According to the method, potassium iodate and sodium iodide are slowly subjected to a neutralization reaction in an acid environment, and hesperidin is oxidized by using a newly prepared low-concentration iodine simple substance to prepare diosmin. The optimal diosmin preparation method is obtained through screening of a large number of experiments, and by means of the method, the purity and yield of diosmin are high, and the impurity content is low; meanwhile, the method is safe, environment-friendly, low in production cost and suitable for industrial production.

The invention opens up a brand new application field of the composition formed by the diosmin and the PD-1 inhibitor, and provides a potential, effective, safe and economical new treatment scheme for gastric cancer patients, especially patients intolerant or drug-resistant to traditional chemotherapy. The invention proves that diosmin can effectively and specifically inhibit the activity of NUAK1 kinase and further inhibit a Wnt / beta-catenin signal channel at the downstream of the NUAK1 kinase. The effect is directly shown as that the protein expression levels of key transcription factors TCF4 and LEF1 are remarkably reduced, so that the function of diosmin serving as a novel NUAK1 inhibitor is proved on the molecular mechanism level, and the tumor inhibition effect of the composition formed by diosmin and the PD-1 inhibitor is remarkably superior to that of the PD-1 inhibitor.

The invention provides a diosmin purification method, and belongs to the field of compound purification. The purification method comprises the following steps: (1) taking a diosmin crude product, and adding the diosmin crude product into an organic solvent; (2) heating the system obtained in the step (1), and adding inorganic base to dissolve the system; (3) adding crystallization purified water into the dissolved clarification system in the step (2), and cooling to crystallize; (4) after cooling and devitrification, keeping the devitrification temperature and filtering; and (5) washing the filter cake with acid, then washing with purified water, and drying to obtain diosmin. The purification method is simple to operate, the solvent is single and easy to recover, and the obtained diosmin is high in yield and purity and has a good application prospect.

The present invention relates to a method for establishing a fingerprint of Hyssopus officinalis, and specifically to a method for determining the fingerprint of 18 characteristic peaks of Hyssopus officinalis, including neochlorogenic acid, chlorogenic acid, diosmin, rosmarinic acid, salvianolic acid B, and montanin, by using an HPLC method. In the method for establishing the fingerprint of the present invention, 328 nm is selected as the measurement wavelength; acetonitrile-0.1% phosphoric acid is used as the mobile phase and gradient elution is performed; preferably 70% methanol is used as the extraction solvent and the extraction method is heated under reflux for 40 minutes. The established method can accurately reflect the overall chemical characteristics of Hyssopus officinalis, is simple and quick, and provides a scientific basis for comprehensively improving its quality.

The utility model discloses high-efficiency diosmin separation equipment which comprises a solution blending tank, a mobile phase blending tank, a chromatographic separation box and a stirring assembly, the solution blending tank and the mobile phase blending tank are the same in structure and each comprise a tank body and an assembly cover connected to the top of the tank body in a sealed mode. The top of the assembling cover is provided with two sets of concentrically-arranged annular pipes, and the annular pipes communicate with the inner side of the assembling cover through connecting pipes. The stirring assembly comprises a mounting shaft and upper and lower layer stirring blades fixedly connected to the mounting shaft, and the mounting shaft is located at the axis of the tank body and the assembling cover and is connected with the stirring assembly through a driving assembly. A box cover is arranged at the top of the chromatographic separation box, a liquid separation pipe is arranged on the inner side of the box cover, and the solution blending tank and the mobile phase blending tank are connected with the liquid separation pipe through a liquid supply pipe group. A liquid collecting tank is arranged at the bottom of the chromatographic separation box and is connected with the chromatographic separation box through a liquid discharging pipe group. According to the equipment, the diosmin separation efficiency is remarkably improved, the operation process is simplified, the separation precision and reliability are improved, and the equipment has a wide application prospect.

This invention belongs to the field of pharmaceutical technology and discloses a pharmaceutical composition for treating TDP-43 proteinopathy, its preparation method, and its application. The pharmaceutical composition includes at least one class A compound and at least one class B compound; class A compound includes at least one selected from sodium aescinate, a sodium aescinate derivative, hederonium, or a hederonium derivative; class B compound includes at least one selected from dehydrated icariin, a dehydrated icariin derivative, diosmin, or a diosmin derivative. This pharmaceutical composition exhibits good therapeutic effects for TDP-43 proteinopathy.

The utility model relates to the technical field of diosmin production equipment, in particular to a reaction kettle for producing diosmin. The reaction kettle for producing diosmin comprises a kettle body, a stirring mechanism, a turbulent flow assembly and a controller, a feeding pipe is mounted at the top of the kettle body, and a discharging pipe is mounted at the bottom of the kettle body; the stirring mechanism is mounted on the kettle body and is used for stirring reactants in the kettle body; the turbulent flow assembly comprises a first turbulent flow mechanism and a second turbulent flow mechanism, the first turbulent flow mechanism and the second turbulent flow mechanism are symmetrically arranged in the kettle body, and the first turbulent flow mechanism is provided with a first air outlet and a second air outlet. The turbulent flow assembly is matched with the stirring mechanism for stirring, so that the hesperidin and the iodine gathered at the bottom of the reaction kettle can be fully mixed with the reaction solvent pyridine, and the mixing efficiency of the hesperidin, the iodine and the reaction solvent pyridine is improved.

The invention relates to application of diosmin in preparation of a medicine for improving emotional symptoms of an IBS (Irritable Bowel Syndrome) patient. According to the application, the application range of the medicine diosmin which has been clinically approved and is suitable for treating various symptoms related to vein lymphatic insufficiency and various symptoms related to acute hemorrhoid attack is expanded to treatment of emotional symptoms of IBS patients for the first time; specifically, the invention provides a new application of diosmin in preparation of medicines for improving the emotional symptoms of IBS patients, breakthrough transformation of new use of old medicines is realized, and strict animal model experiments prove that diosmin can effectively improve the emotional symptoms of IBS model mice and IBS patients. Besides, as a clinically approved medicine, the safety, pharmacokinetics and dosage range of diosmin in a human body are fully verified, so that a solid foundation is provided for the diosmin to quickly enter a clinical test stage of emotional symptoms of IBS patients, the research and development period is remarkably shortened, and the transformation risk is reduced.

The invention belongs to the technical field of cosmetics, and discloses a diosmin-containing depilatory paste with a soothing effect and a preparation method thereof, the depilatory paste comprises the following components by mass: 50-80% of water, 6-15% of fatty alcohol, 3-6% of an emulsifier, 10-25% of an emollient, 3-8% of mercaptoacetate, 0.1-0.4% of a pH regulator, and 0.01-0.1% of diosmin. Diosmin with good alkaline stability is introduced into a depilatory paste system with the pH value of about 12.5, the problem that the activity of a traditional soothing component is reduced in a strong alkaline environment is solved, the skin irritation reaction caused by chemical depilation is effectively relieved, and patch tests prove that the depilatory paste is low in skin irritation, obvious in soothing effect and free of toxic and side effects. The composition is suitable for sensitive skin users and has a good application prospect.

The present invention belongs to the technical field of pharmaceuticals. Disclosed are a pharmaceutical composition for treating a TDP-43 proteinopathy, and a preparation method therefor and the use thereof. The pharmaceutical composition comprises at least one of each of compounds of class A and compounds of class B. The compounds of class A comprise at least one of sodium aescinate, a sodium aescinate derivative, hederagenin or a hederagenin derivative; and the compounds of class B comprise at least one of dehydrated icaritin, a dehydrated icaritin derivative, diosmin or a diosmin derivative. The pharmaceutical composition has a good therapeutic effect on the TDP-43 proteinopathy.

The invention belongs to the technical field of medicines, and discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial ischemia-reperfusion, the pharmaceutical composition is composed of diosmin, etomoxazide and fluoxetine, and the mass ratio of diosmin to etomoxazide to fluoxetine is 1: 1: 1. Western blot proves that diosmin, etomagazide and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro heart electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion. TTC staining proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial ischemia reperfusion. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion, the clinical application of the composition to the ventricular arrhythmia after myocardial ischemia-reperfusion can be further developed.